Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy

Journal of Nuclear Medicine

Volumn 45, Issue 10, 2004, Pages 1660-1668

  Nguyen, Charles ^a   Faraggi, Marc ^a   Giraudet, Anne Laure ^a   De Labriolle Vaylet, Claire ^b   Aparicio, Thomas ^a   Rouzet, François ^a   Mignon, Michel ^a   Askienazy, Serge ^a   Sobhani, Iradj ^c  

^a CENTRE HOSPITALIER   (France)

^b ARMAND TROUSSEAU HOSPITAL   (France)

^c HENRI MONDOR HOSPITAL   (France)

Author keywords

111In pentetreotide; 131I metaiodobenzylguanidine; Efficacy; Neuroendocrine tumor; Radionuclide therapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ANALGESIC AGENT; ANGIOPEPTIN; FLUOROURACIL; OCTREOTIDE; PENTETREOTIDE IN 111; STREPTOZOCIN; (3 IODOBENZYL)GUANIDINE; DRUG DERIVATIVE; PENTETREOTIDE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HUMAN; MALE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; TREATMENT CONTRAINDICATION; TUMOR GROWTH; TUMOR LOCALIZATION; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; FOLLOW UP; GASTROINTESTINAL TUMOR; LONGITUDINAL STUDY; METHODOLOGY; MIDDLE AGED; PANCREAS TUMOR; SALVAGE THERAPY; SURVIVAL; TERMINAL CARE; TREATMENT FAILURE; TREATMENT OUTCOME; VALIDATION STUDY;

3-IODOBENZYLGUANIDINE; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; RADIOPHARMACEUTICALS; SALVAGE THERAPY; SOMATOSTATIN; SURVIVAL ANALYSIS; TERMINAL CARE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 16544387698     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Mignon M. Natural history of neuroendocrine enteropancreatic tumors. Digestion. 2000;62(suppl 1):51-58.
2. Caplin ME, Buscombe JR, Hilson AJ, et al. Carcinoid tumour. Lancet. 1998;352:799-805.
3. Frank M, Klose KJ, Wied M, et al. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic gastroenteropancreatic tumors. Am J Gastroenterol. 1999;94:1381-1387.
4. Kim YH, Ajani JA, Carrasco CH, et al. Selective hepatic arterial chemoembolisation for liver metastasis in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest. 1999;17:474-478.
5. 111In-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med. 2003;44:1-6.
6. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-731.
7. Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med. 2002;32:84-91.
8. Lebtahi R, Cadiot G, Sarda L, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med. 1997;38:853-858.
9. Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur J Nucl Med. 1994;21:561-581.
10. Seregni E, Chiti A, Bombardieri E. Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results. Eur J Nucl Med. 1998;25:639-658.
11. Hoefnagel CA. Radionuclide therapy revisited. Eur J Nucl Med. 1991;18:408-431.
12. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26:1439-1447.
13. De Jong M, Krenning E. New advances in peptide receptor radionuclide therapy. J Nucl Med. 2002;43:617-620.
14. De Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med. 2002;32:133-140.
15. 3-Octreotide: the experience of the European Institute of Oncology Group. Semin Nucl Med. 2002;32:141-147.
16. 90Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med. 2002;32:148-155.
17. Faraggi M, Gardin I, De Labriolle-Vaylet C, Moretti L, Bok B. The influence of tracer localization on the electron dose rate delivered to the cell nucleus. J Nucl Med. 1994;35:113-119.
18. 1]-octreotide in patients with neuroendocrine tumors. J Nucl Med. 2000;41:1514-1518.
19. Mariani G, Bodei L, Adelstein SJ, Kassis AI. Emerging roles for radiometabolic therapy of tumors based on Auger electron emission. J Nucl Med. 2000;41:1519-1521.
20. 1]-octreotide: a case history. Ann NY Acad Sci. 1994;733:496-506.
21. Krenning EP, Kooij PPM, Pauwels S, et al. Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion. 1996;57(suppl 1):57-61.
22. 1-octreotide in midgut carcinoid syndrome. J Nucl Med. 1996;37:1519-1521.
23. Caplin ME, Hons BS, Hodgson HJ, et al. Multimodality treatment for gastric carcinoid tumor with liver metastases. Am J Gastroenterol. 1998;93:1945-1948.
24. McCarthy KE, Woltering EA, Espenan GD, Cronin M. In situ radiotherapy with 111In-pentetreotide: initial observations and future directions. Cancer J Sci Am. 1998;4:94-102.
25. Cornelius A, Murren J, Zoghbi S, et al. In-111-Octreotide therapy: phase I-II trial [abstract]. J Nucl Med. 1999;40(suppl):19P.
26. Tiensuu Janson E, Eriksson E, Öberg K, et al. Treatment with high dose [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors: evaluation of therapeutic and toxic effects. Acta Oncol. 1999;38:373-377.
27. Espenan GD, Nelson JA, Fisher DR, et al. Experiences with high dose radiopeptide therapy: the health physics perspective. Health Phys. 1999;76:225-235.
28. Krenning EP, Valkema R, Pauwels S, et al. Radiolabeled somatostatin analogue( s): peptide receptor scintigraphy and radionuclide therapy. In: Mignon M, Colombel JF, eds. Recent Advances in the Pathophysiology and Management of Inflammatory Bowel Diseases and Digestive Endocrine Tumors. Paris, France: John Libbey Eurotext; 1999:220-228.
29. 0]octreotide: the Rotterdam experience. Semin Nucl Med. 2002;32:110-122.
30. Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-Pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002;32:123-132.
31. De Jong M, Rolleman EJ, Bernard BF, et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med. 1996;37:1388-1392.
32. Mc Ewan AJB, Amyotte G, Morin C, Mc Gowan DG, Fields ALA, Smylie M. High dose I-131 mIBG therapy in patients with metastatic carcinoid tumors [abstract]. J Nucl Med. 1996;37(suppl):237P.
33. Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H, Beijnen JH. Palliative effects of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol. 1996;14:1829-1838.
34. Bongers V, De Klerk JMH, Zonnenberg BA, De Kort G, Lips CJM, Van Rijk PP. Acute liver necrosis induced by iodine-131-MIBG in the treatment of metastatic carcinoid tumors. J Nucl Med. 1997;38:1024-1026.
35. 131I-MIBG therapy for neuroblastoma and carcinoid tumours. Nucl Med Commun. 2001;22:367-374.
36. 111In- DTPA-octreotide. Eur J Nucl Med. 2001;28:1743-1750.
37. 0]octreotide in patients. Eur J Nucl Med. 2001;28:1319-1325.
38. Krenning EP, Bakker WH, Kooij PPM, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med. 1992;33:652-658.
39. 111In-DTPA-D-Phe-1-OCT. Eur J Nucl Med. 1996;23:1388-1399.
40. Lamberts SWJ, Bakker WH, Reubi J-C, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med. 1990;323:1246-1249.